Afficher la notice abrégée

Optimizing co-prescription of clozapine and antiseizure medications: a systematic review and expert recommendations for clinical practice

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorVERDOUX, Helene
IDREF: 115951903
dc.contributor.authorQUILES, Clelia
dc.contributor.authorDE LEON, Jose
dc.date.accessioned2024-06-26T12:13:47Z
dc.date.available2024-06-26T12:13:47Z
dc.date.issued2024-05-01
dc.identifier.issn1744-7607en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/200656
dc.description.abstractEnINTRODUCTION: Antiseizure medication (ASM) add-on to clozapine may be efficient to target clozapine-resistant mood or psychotic symptoms or clozapine-related adverse drug reactions (ADR) such as seizures. We aimed to synthesize the information relevant for clinical practice on the risks and benefits of clozapine-ASM co-prescription. AREAS COVERED: Articles were identified with MEDLINE, Web of Sciences and PsycINFO search from inception through October 2023. The review was restricted to ASM with mood-stabilizing properties or with potential efficacy for resistant psychotic symptoms (valproate (VPA), lamotrigine, topiramate, carbamazepine, oxcarbazepine). EXPERT OPINION: VPA add-on to clozapine is associated with a high risk of serious ADR (myocarditis, neutropenia, pneumonia) mostly explained by complex time-dependent drug-drug interactions. The initial inhibitory effects on clozapine metabolism require slow titration to avoid immuno-allergic reactions. After the titration period, VPA has mainly inductive effects on clozapine metabolism that are more marked in smokers requiring therapeutic drug monitoring. Lamotrigine and topiramate add-on may be recommended as the first-line treatment for clozapine-related seizures, but there is limited evidence regarding the efficacy of this strategy for clozapine-resistant psychotic symptoms. Carbamazepine should not be co-prescribed with clozapine because of its potential for agranulocytosis and for inducing clozapine metabolism.
dc.language.isoENen_US
dc.subject.enClozapine
dc.subject.enAdverse Drug Reaction
dc.subject.enAntiseizure Medication
dc.subject.enDrug-Drug Interaction
dc.subject.enTherapeutic Drug Monitoring
dc.title.enOptimizing co-prescription of clozapine and antiseizure medications: a systematic review and expert recommendations for clinical practice
dc.title.alternativeExpert Opin Drug Metab Toxicolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1080/17425255.2024.2343020en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed38613254en_US
bordeaux.journalExpert Opinion on Drug Metabolism and Toxicologyen_US
bordeaux.page347-358en_US
bordeaux.volume20en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue5en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamAHEAD_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04625879
hal.version1
hal.date.transferred2024-06-26T12:13:49Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Expert%20Opinion%20on%20Drug%20Metabolism%20and%20Toxicology&rft.date=2024-05-01&rft.volume=20&rft.issue=5&rft.spage=347-358&rft.epage=347-358&rft.eissn=1744-7607&rft.issn=1744-7607&rft.au=VERDOUX,%20Helene&QUILES,%20Clelia&DE%20LEON,%20Jose&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée